Back Back
Cell No. : Cell Name
HPS0164 :  update : 2023/06/22
CommentDisease specific iPS cell line derived from a patient : Muscular dystrophy, Duchenne type. iPS cells were created using the Sendai virus vector. Cryopreserved by vitrification method.
Comment from the depositor
Terms and conditions1) The iPS cells created using the Sendai virus vector are now available must be observed when using SeV-iPS cells. 2) In relation to the for-profit organizations, please contact iPS Academia Japan, Inc., prior to the utilization of iPS cells. 3) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
Order Form Order Form(C-0042.pdf)   Approval Form(C-0057.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 10s
Tissue skin
Disease name Muscular dystrophy, Duchenne type
Classification iPS
Recombinant recombinant
Lifespan infinite
Morphology ES-like
Cellosaurus(Expasy) CVCL_T929
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM/HamF12 (2mM L-Glutamine) + 20% KSR + 0.1mM NEAA + 0.1mM 2-Mercaptoethanol + 5ng/ml human basic FGF
Antibiotics Free
Passage method 0.25% Trypsin + 0.1% collagenase type IV + 20% KSR + 1mM CaCl2 + PBS(-)
Coating dish 0.1% gelatin coated dish
Culture information Passage ratio 1 : 3-5 split
SC frequency Subculture : once/4-6 days, Medium Renewal : every day
Temperature 37 ℃
CO2 concentration 3 %
Feeder cells MEF
Feeder treatment X-rays 5000R (or MMC)
Feeder seed cells 3-5 x 10 5 cells/60 mm dish
Freeze medium DAP213 : Medium + 2M DMSO + 1M Acetamide + 3M Propyleneglycol
Freezing method Vitrification
Mycoplasma (-)
STR(human) OK
deposit info
lot info
Relational File deposit infolot info
Reference information Reference 0
User's Publication 5

To topTop

To topTop
User's Publication
21255  Chai AC, Chemello F, Li H, Nishiyama T, Chen K, Zhang Y, Sánchez-Ortiz E, Alomar A, Xu L, Liu N, Bassel-Duby R, Olson EN.  Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.  Mol Ther Nucleic Acids  2023  32:522-535  PubMed ID: 37215149   DOI: 10.1016/j.omtn.2023.04.009
20855  Zhang Y, Li H, Nishiyama T, McAnally JR, Sanchez-Ortiz E, Huang J, Mammen PPA, Bassel-Duby R, Olson EN.  A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.  Mol Ther Nucleic Acids  2022  29:525-537  PubMed ID: 36035749   DOI: 10.1016/j.omtn.2022.07.024
20418  Zhang Y, Nishiyama T, Li H, Huang J, Atmanli A, Sanchez-Ortiz E, Wang Z, Mireault AA, Mammen PPA, Bassel-Duby R, Olson EN.  A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.  Mol Ther Methods Clin Dev  2021  22:122-132  PubMed ID: 34485599   DOI: 10.1016/j.omtm.2021.05.014
10738  Long C, Li H, Tiburcy M, Rodriguez-Caycedo C, Kyrychenko V, Zhou H, Zhang Y, Min YL, Shelton JM, Mammen PPA, Liaw NY, Zimmermann WH, Bassel-Duby R, Schneider JW, Olson EN.  Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.  Sci Adv  2018  4:eaap9004  PubMed ID: 29404407   DOI: 10.1126/sciadv.aap9004
10265  Zhang Y, Long C, Li H, McAnally JR, Baskin KK, Shelton JM, Bassel-Duby R, Olson EN.  CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.  Sci Adv  2017  3:e1602814  PubMed ID: 28439558   DOI: 10.1126/sciadv.1602814

Back Back Return Top Page